Evidence map›Paper›PMID 42203967›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Feasibility of short imaging protocols for [

Lisa Tagnin, Julia S Dorneich, Marianthi Zeinaki, Letizia Vogler, Laura Sanzo, Johannes S Gnörich, Sabrina Katzdobler, Ilias Masouris, Alexander Jäck, Alexander M Bernhardt and 22 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Lisa TagninDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Julia S DorneichDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Marianthi ZeinakiDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Letizia VoglerDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Laura SanzoDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Johannes S GnörichDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Sabrina KatzdoblerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Ilias MasourisGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Alexander JäckGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Alexander M BernhardtDepartment of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.
Boris-Stephan RauchmannDepartment of Neuroradiology, University Hospital of Munich, LMU Munich, Munich, Germany.
Sophia StoeckleinDepartment of Radiology, University Hospital of Munich, LMU Munich, Munich, Germany.
Marcel SimmetDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Emanuel JosephDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Simon LindnerDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Norman KoglinLife Molecular Imaging GmbH, a Lantheus Company, Berlin, Germany.
Andre MuellerLife Molecular Imaging GmbH, a Lantheus Company, Berlin, Germany.
Andrew W StephensLife Molecular Imaging GmbH, a Lantheus Company, Berlin, Germany.
Gérard N BischofLife Molecular Imaging GmbH, a Lantheus Company, Berlin, Germany.
Lukas K FrontzkowskiDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Nicolai FranzmeierDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany.
Jonathan A GernertInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Franziska HopfnerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Günter U HöglingerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Robert PerneczkyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Carolin KurzDepartment of Psychiatry and Psychotherapy, University Hospital of Munich, LMU Munich, Munich, Germany.
Tania KümpfelInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Martin KerschensteinerInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Franziska S ThalerInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Matthias BrendelDepartment of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninstraße 15, 81377, Munich, Germany. Matthias.Brendel@med.uni-muenchen.de.ORCID 0000-0002-9247-2843

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction[

methodsDynamic 60-min [

resultsStatic images acquired between 10 and 60 min p.i. showed good image contrast and signal-to-noise ratio. SUVr of lesions increased over time and approached a plateau at approximately 50-60 min p.i.. The strongest agreement between SUVr and DVR was observed between 30 and 50 min p.i.. Late-phase SUVr outperformed kinetic parameters in discriminating lesions from healthy tissue in both AIE and MSA.

conclusionShort static [

Indexed as

EncephalitisHashimoto DiseaseMultiple System AtrophyPositron-Emission TomographyAdultAgedFeasibility StudiesFemaleHumansMaleMiddle AgedTime Factors[18F]fluordeprenyl-D2Autoimmune encephalitisMAO-B PETMultiple system atrophyShort imaging window

Identifiers

PMID42203967
PMCPMC13421227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.